(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 5. FGF9 induces sub-mesothelial mesenchymal proliferation independent of
SHH signaling. (A-C) Two histologically distinct regions of
mesenchymal cells are evident at E13.5. A population of sub-epithelial
mesenchymal cells (SEM) wrap around the epithelial ducts, and a loose network
of non-oriented sub-mesothelial mesenchymal cells (SMM) inhabit the area
between the mesothelium and the SEM (A). In
Fgf9/ lungs, the SMM is largely absent (B),
whereas a large expanse of SMM is present in Fgf9dox(48)
lungs (C). (D-G) Whole-mount immunohistochemistry with
anti-phosphohistone H3 (PH3) identified an increase in PH3-labeled cells in
E11.5 lung explants incubated with FGF9 for 24 hours (E), compared with
BSA-treated controls (D). Cyclopamine-only treated explants showed decreased
overall proliferation (G). Explants incubated with both FGF9 and cyclopamine
(F) appeared similar to FGF9-only treated explants (E) at low magnification.
At higher magnification, cyclopamine-treated cultures (F',G')
showed reduced cell proliferation in the SEM, whereas FGF9 increased
proliferation in the SMM (E',F'). Explants treated with both
cyclopamine and FGF9 (Cy/F9) have a combined effect, with increased PH3
labeling in the SMM and decreased labeling in the SEM (F9). (H-K)
Staining for active caspase 3 demonstrates high levels of apoptosis in
cyclopamine-treated explants (K), compared with relatively few labeled cells
in BSA or FGF9-treated explants (H,I). A moderate amount of active caspase 3
staining is evident in the SEM of Cy/F9-treated explants, indicating a partial
rescue of apoptosis by FGF9 (J). (L,M) Quantification of cell
proliferation (PH3 labeled nuclei/unit area) in explants treated with FGF9 and
cyclopamine (Cy) for 24 (L) and 48 (M) hours. Student t-test,
***P<0.0001; **P<0.001;
*P<0.01.